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ABSTRACT 
Volatile anesthetics such as sevoflurane attenuate inflammatory processes, 
thereby significantly impacting patient outcome. Their inhalative administration is, 
however, strictly limited to controlled environments such as operating theatres and thus 
an intravenously injectable immunomodulatory drug would offer distinct advantages. 
As protective effects of volatile anesthetics have been associated with the presence of 
trifluorinated carbon groups in their basic structure, we investigated in this study the 
water-soluble sevoflurane metabolite hexafluoro-2-propanol (HFIP) as a potential 
immunomodulatory drug in a rat model of endotoxic shock. Male Wistar rats were 
subjected to intravenous lipopolysaccharide (LPS) and thereafter were treated with 
HFIP. Endpoints were plasma and tissue inflammatory mediators, neutrophil invasion, 
tissue damage, and hemodynamic stability. In an endotoxin-induced endothelial cell 
injury model, underlying mechanisms were elucidated using gene expression and gene 
reporter analyses. HFIP significantly reduced the systemic inflammatory response and 
decreased endotoxin-induced tissue damage. Additionally, the LPS-provoked drop in 
blood pressure of animals was resolved by HFIP treatment. Pathway analysis revealed 
that the observed attenuation of the inflammatory process was associated with reduced 
NF-κΒ activation and suppression of its dependent transcripts. Taken together, 
intravenous administration of HFIP exerts promising immunomodulatory effects in 
endotoxemic rats. The possibility of intravenous administration would overcome 
limitations of volatile anesthetics and thus HFIP might therefore represent an interesting 
future drug candidate for states of severe inflammation. 
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INTRODUCTION 
Sepsis accompanied by multiple organ failure is a leading cause of hospital 
morbidity and mortality in intensive care units (ICU) and is associated with tremendous 
financial costs [1]. The time elapsed until the focus of the infection is under control 
ultimately determines the fate of the patient [2]. Numerous supportive therapeutic 
strategies including early fluid resuscitation, microbial screening, and empiric 
antimicrobial therapy have been implemented to bridge the time to source control [3]. 
Volatile anesthetics provide beneficial effects in perioperative states of hypoxia-
reoxygenation and ischemia-reperfusion injury [4, 5]. The improved outcome is 
accompanied by an altered immune response resulting in attenuation of the 
inflammatory response and tissue damage [6-9]. In recent work, the volatile anesthetic 
sevoflurane has been shown to improve survival in septic peritonitis in mice when 
applied as brief conditioning [10, 11], and has been discussed as an additional 
supportive treatment modality in sepsis [7]. 
The application of sevoflurane is strictly limited to controlled environments such 
as operating theaters or ICU due to its route of administration and anesthetic effects. To 
overcome this limitation of volatile anesthetics and to provide the protective effects to a 
broader target group, numerous attempts have been undertaken to encapsulate volatile 
anesthetics in lipid emulsions for intravenous administration [12]. Despite major efforts, 
none of these emulsions are currently used as part of our daily clinical routine. It would 
therefore be favorable to isolate the immunomodulating properties of volatile 
anesthetics in an injectable formulation, and to separate them from the anesthetic effect. 
Interestingly, the presence of hexafluoro-2-propanol (HFIP), a water-soluble 
primary metabolite of the volatile anesthetic sevoflurane, has been associated with 
attenuated secretion of endotoxin-stimulated inflammatory mediators in vitro [13]. In 
addition, HFIP has been shown to improve 7-day survival in a model of septic 
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peritonitis in mice [14]. At present, no information is available on the underlying 
mechanisms of the beneficial inflammatory or immunomodulatory effect of HFIP. In 
particular, with regard to a future therapeutic administration, the effect also has to be 
reproducible in a different species and in different models of sepsis (type of sepsis 
induction; ICU-like conditions with sedation and mechanical ventilation). We therefore 
chose a well-established rat model of lipopolysaccharide (LPS)-induced inflammation 
that mimics the initial phase of sepsis [15] to study the early immunomodulatory effect 
of HFIP (Fig. 1A). We hypothesized that both HFIP and sevoflurane would attenuate 
the inflammatory response, reduce the invasion of effector cells, and decrease tissue 
damage evoked by endotoxin challenge. To uncover underlying molecular mechanisms 
of the effects provided by HFIP, we analyzed the gene expression profile of human 
microvascular endothelial cells (HMVEC) following stimulation with LPS (Fig. 1B). 
Special attention was paid to pathways downstream of the mammalian LPS receptor, 
Toll-like receptor 4 (TLR4) [16, 17], where we expected significant changes due to 
HFIP-mediated modulation of TLR4-activated pro-inflammatory responses.  
Herein, we demonstrate in the rat model of acute endotoxemia that intravenous 
injection of HFIP reduces the levels of pro-inflammatory mediators in plasma and 
tissue, decreases subsequent neutrophil invasion, and attenuates apoptosis in internal 
organs. These effects are associated with suppression of NF-κΒ activation and 
expression of NF-κΒ-dependent transcripts. 
 
EXPERIMENTAL PROCEDURES 
Ethics statement – All animals were housed and handled in accordance with 
protocols approved by the local animal care and use committee, Zurich, Switzerland 
(No. 156/2010). 
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Wistar rats – Pathogen-free, adult male Wistar rats weighing 350 – 500g 
(Charles River, Sulzfeld, Germany) were used. The animals were allowed to acclimate 
for at least one week prior to initiation of procedures and were housed under a 12/12-hr 
light/dark regimen in standard cages at 22 ± 1°C. Food and water were supplied ad 
libitum. 
Animal preparation – Anesthesia was induced with intraperitoneal sodium 
thiopental (100mg/kg; Pentothal, Ospedalia AG, Hünenberg, Switzerland). The left 
jugular vein was cannulated with a sterile 22-gauge catheter (BD Insyte; Becton 
Dickinson S.A., Madrid, Spain) for fluid administration and maintenance of anesthesia 
using continuous propofol infusion (Disoprivan 1%, AstraZeneca, Zug, CH; 
10mg/kg/h). For animals of the sevoflurane group, intravenous application of propofol 
was stopped, replaced by a 30-min anesthesia with sevoflurane, and re-initiated 
thereafter. Arterial blood pressure was measured continuously with a sterile 
polyethylene catheter placed into the left carotid artery (pressure transducer; Spacelabs, 
Hertford, United Kingdom). Arterial blood samples (900 µl) were taken hourly for 
blood gas analyses and determination of inflammatory mediator levels. The blood 
volume was substituted by Ringer’s lactate (B.Braun, Melsungen, Germany) in a 1:4 
ratio (3.6 mL). A tracheotomy was performed and the rats were mechanically ventilated 
using the pressure-controlled mode (Servo Ventilator 300; Maquet, Solna, Sweden). 
Peak inspiratory pressure was 14 cm H2O, with a positive end-expiratory pressure of 3 
cm H2O. The fractional inspired oxygen concentration (FiO2) was 0.6, 
inspiratory:expiratory ratio was 1:2, respiratory rate was 30/min and was corrected for 
normoventilation (arterial target CO2: 4.6-5.2 kPa) according to the blood gas analyzer. 
Body temperature was maintained at 37°C using a warming lamp.  
Design of animal experiments – Thirty-six male Wistar rats were randomly 
assigned to blocks of two animals. The blocks were again randomized into the following 
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groups: I) LPS group (n=10), which received intravenous 1 mg/kg Escherichia coli 
endotoxin (LPS, E. coli endotoxin serotype 055:B5; Sigma-Aldrich, Buchs, 
Switzerland; dissolved at a concentration of 1 mg/mL in phosphate-buffered saline, 
(PBS) Kantonsapotheke Zurich, Zurich, Switzerland); II) LPS+HFIP group (n=7), 
which was treated identically to the LPS group with the additional administration of 67 
mg/kg HFIP (Sigma-Aldrich, Buchs, Switzerland) in Ringer’s lactate over 30 min after 
LPS injection; III) LPS+sevoflurane group (n=8), which was treated identically to the 
LPS group but with the additional administration of sevoflurane (Sevorane; Abott, Baar, 
Switzerland) using the Anesthetic Conserving Device (AnaConDa, Sedana Medical, 
Uppsala, Sweden) over 30 min after LPS injection [18] while propofol infusion was 
stopped and reinitiated after the 30min sevoflurane application; IV) CONTROL group 
with PBS instead of LPS (n=5); V) HFIP group in which animals received PBS and 67 
mg/kg HFIP (n=5). Based on results from in vitro studies [19], we empirically decided 
to administer a dose of 67 mg/kg HFIP to rats, which corresponds to 0.39 mmol/kg total 
body weight (BW) or 4 mmol/L blood volume. This dose is comparable to previous 
experiments [14, 19] and significantly lower than the LD50 (around 180 mg/kg in mice 
when administered intravenously) [14].  To set these values in to the context of human 
subject exposures, 0.05 mmol/kg BW HFIP (primary metabolite) was measured after 3 
hours of sevoflurane anesthesia [20]. In preliminary experiments, we administered 134 
mg/kg (≈8 mmol/L blood) which is analogous to values obtained from in vitro 
experiments [13]. However, after bolus injection of the double dose, within two hours 
100% mortality was observed in endotoxemic rats. One animal died due to technical 
reasons during the monitoring phase of the experimental procedure, which is why only 7 
(and not 8) animals in the LPS+HFIP group were included in the analysis. The 
concentration of sevoflurane during the 30 min treatment was targeted at 1–2 vol% 
(0.5–1 minimum alveolar concentration, respectively) (LPS+sevoflurane group). All 
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animals received additional Ringer’s lactate (30mL/kg) after injection of LPS over a 
time period of 1 hour. The animals were euthanized 6 hours after endotoxin infusion. 
Blood was drawn from the inferior vena cava. Finally, the lung (after bronchoalveolar 
lavage), the spleen, the liver, and the kidneys were snap-frozen in liquid nitrogen and 
tissue, bronchoalveolar lavage fluid (BALF) and plasma were stored at -80°C for 
isolation of RNA, cryosections, and determination of inflammatory cytokine levels (Fig. 
1A). 
Enzyme-linked immunosorbent assays (ELISA) used for assessment of 
inflammatory mediators – Sandwich ELISAs were performed according to the 
manufacturer’s protocol, assessing monocyte chemoattractant protein 1 (MCP-1, BD 
Biosciences, San Diego, CA), interleukin 6 (IL-6, R&D Systems, Minneapolis, MN), 
and cytokine-induced neutrophil chemoattractant-1 (CINC-1, R&D Systems, 
Minneapolis, MN) in plasma and BALF. According to the manufacturer, the lower 
detection limits were 30 pg/mL for MCP-1, 30 pg/mL for IL-6, and 15 pg/mL for 
CINC-1.  
Real-time PCR analysis of inflammatory mediators in tissue – Total RNA was 
isolated from liver, spleen, kidney and lung. After homogenization using 1.4 mm 
ceramic beads (MagNA Lyser Green Beads, Roche) and a Precellys homogenizer 
(Bertin Corp, Rockville, MD) for 2 x 30 sec at 6800 rpm, RNA was purified using the 
RNeasy minikit (Qiagen, Basel, CH) and cDNA was produced with 0.5 µg RNA in the 
HC cDNA Reverse Transcription Kit from (Qiagen, Basel, CH). Quantitative PCR was 
performed using the FastStart Universal Probe Master PCR Mix (Roche, Basel, CH), 
with labelled probes (Roche Probe Library, Basel, CH) and primers (Microsynth, 
Balgach, CH) designed for CINC, IL-6, MCP-1 and 18S. The final reaction volume of 
the assay was 15 µl and the PCR was performed on a LightCycler 480 Real Time PCR 
System (Roche, Basel, CH). The comparative Ct method was used for quantification of 
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the gene expression. The Cp values (Secondary Derivative Method, Roche) of the 
samples were normalized to the housekeeping gene (18S). 
Determination of neutrophils in tissue – Frozen kidney and liver tissue was cut 
into 6 µm sections using the Cryostat HYRAX C60 (Zeiss, Jena, Germany). These 
sections were dried at room temperature for 1 hour and fixed with 4% 
paraformaldehyde for 10 min. After 3 washes with PBS, immunofluorescence staining 
on neutrophils was performed using a mouse anti-rat RP1 antibody (PharMingen, BD 
Biosciences, Allschwil, CH). After one hour incubation at 4°C, the sections were 
washed three times with PBS and subsequently incubated with the secondary antibody, 
Alexa Fluor 568 goat-anti-mouse IgG (Invitrogen, Life Technologies, CH) and 
diamidino-2-phenylindole (DAPI) for 1 hour at 4°C. The sections were scanned, using a 
Mirax Slidescanner (Zeiss, Feldbach, CH). Fluorescence intensity was quantified using 
the spotting method in the Imaris Image Processing and Analysis Software (Bitplane, 
Zurich, CH). 
Measurement of caspase-3 activity in tissue – Caspases are cysteine proteases 
that play a key role in apoptotic signaling. These molecular scissors cleave their 
substrates after an aspartate residue. Kidney, lung, liver, and spleen tissue was isolated 
from rats and and immersed in ice-cold extraction buffer (25 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 5 mM MgCl2, 1 mM ethylene glycol 
tetraacetic acid (EGTA), 1 mM phenylmethanesulfonylfluoride (PMSF), 1 µg/mL 
protease inhibitor mix, all from Sigma, Allschwil, CH) with 1.4 mm ceramic beads 
(MagNA Lyser Green Beads, Roche, Switzerland) and homogenized using a Precellys 
homogenizer (2 x 30sec @ 6800 rpm). The supernatant was centrifuged at 20.000 rcf 
for 30 min at 4°C. Duplicate sets of protein samples (40 µg, determined by Bio-Rad 
protein assay) were incubated with fluorescent caspase-3 substrate Ac-DEVD-AMC 
(PeptaNova, Sandhausen, Germany) in extraction buffer with 1 mM DTT, and enzyme 
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activity was measured for 30 min at 350 nm (excitation) / 465 nm (emission) using a 
fluorescent spectrophotometer (Infinite M1000 Pro, Tecan, Männedorf, CH). As a 
positive control, 2 nM active human caspase-3 was added to the reaction (Institute of 
Biochemistry, University of Zurich, a gift from Dr. Heidi Roschitzki-Voser). 
Determination of direct and indirect renal and hepatic tissue damage markers –
Creatinine, blood urea nitrogen (BUN), aspartate transaminase (AST) and bilirubin were 
assessed using a biochemical analyzer (DRI-CHEM4000i, FUJIFILM, Japan). α1-
microglobulin, a low molecular weight protein, was used as a marker for tubular 
function. Urine samples were collected at fixed time points; volumes and specific 
gravity were determined. All samples were centrifuged (1000 x g for 5 min), diluted 
1:1000, and analyzed with a commercial α1-microglobulin ELISA (Hölzel Diagnostika 
GmbH, Cologne, Germany). The detection range was between 0.53 and 100 ng/mL.  
Design of the experiments with human microvascular endothelial cells 
(HMVEC) – Human microvascular endothelial cells (CC-2815) derived from normal 
human microvascular blood vessels were purchased from Lonza (Verviers, Belgium) 
and cultured as described  [13].. For gene expression analysis, cells were exposed for 6 
hours to 20 µg/mL LPS (dissolved in PBS) from Escherichia coli serotype 055:B5 
(Sigma-Aldrich, Buchs, Switzerland) to induce an inflammatory response (control cells 
were incubated with PBS) and co-exposed to 8 mmol/L HFIP (Sigma-Aldrich, Buchs, 
Switzerland) as in our previous study [13] (Fig. 1B).  
Gene array analysis – Total RNA from HMVEC was extracted as described 
above. The quality of the isolated RNA was evaluated using NanoDrop ND 1000 
(NanoDrop Technologies, Delaware, USA) and Bioanalyzer 2100 (Agilent, Waldbronn, 
Germany). Genome-wide RNA levels were assessed using the human gene expression 
SurePrint GE3 (8 × 60 K) microarray according to the manufacturer's protocol (Agilent). 
An Agilent Microarray Scanner (Agilent p/n G2505C) was used to measure the 
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fluorescence intensity emitted by the labeled targets. Raw data processing was 
performed using the Agilent Scan Control and Agilent Feature Extraction Software 
Version 10. In total, twelve samples with LPS- or PBS-stimulated HMVEC, from which 
6 samples were treated with HFIP, were hybridized on microarrays. One sample of the 
LPS+HFIP group was lost due to technical error during the hybridization procedure. 
Data were deposited in NCBI's Gene Expression Omnibus (GEO). 
Differential expression and pathway analysis – Differential expression analysis 
was performed using the limma package in R/Bioconductor (Fred Hutchinson Cancer 
Research Center, Seattle, WA) in which transcripts of genes were ranked according to 
fold-change and significance. Clustering of the selected genes was achieved 
using hierarchical clustering with Euclidean distance metric and average linkage to 
generate the hierarchical tree. Pathway analysis of significantly regulated genes was 
performed using MetaCore (GeneGo, St. Joseph, MI). MetaCore is a web-based 
software suite for functional analysis of experimental data, based on a manually curated 
database of human protein-protein, protein-DNA, and protein-compound interactions, as 
well as metabolic and signaling pathways. 
Luciferase assay of AP-1 and NF-κB activity – Endothelial cells were grown in a 
96-well plate to 70% confluence and starved overnight as described [19]. Diluted Plus 
Reagent (1:40 in Optimem, both from Invitrogen) was mixed with 100 ng DNA per well 
(Cignal Reporter Assay, Quiagen, Venlo, NL) and added to the same volume of diluted 
lipofectamine LTX (1:12.5 in Optimem, both from Invitrogen). Complex formation was 
allowed for 5 minutes at room temperature and cells were transfected for 4h in the 
incubator. Thereafter transfection media was replaced by growth media for 6h and 
changed back to serum-free media overnight. After exposure to 20 µg/ml LPS with or 
without 4 mM HFIP for 4 hours, luciferase activity was measured by Dual Luciferase 
Reporter Assay (Promega, Fitchburg, WI, USA) according to the manufacturer’s 
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protocol. Activity of activator protein-1 (AP-1) and nuclear factor-kappa B (NF-κB) 
were corrected for transfection efficiency (firefly luciferase activity divided by renilla 
luciferase activity).  
Influence of HFIP on the toll-like receptor 4 (TLR4) signaling pathway – After 
observing the gene expression profiles, we performed additional experiments in 
HMVEC using 20 µg/mL LPS, 10 nM phorbol-12-myristate-13-acetate (PMA) 
(Calbiochem©, Merck KGaA, Darmstadt, Germany) and 20 nM tumor necrosis factor-α 
(TNF-α) (R&D Systems, Abingdon, UK) as stimulants of an inflammatory response. 
Hexafluoro-2-propanol was administered at a concentration of 4 mmol/L. After 6 hours 
of exposure, we measured inflammatory mediator expression in supernatants using 
human IL-6 ELISA and human CINC-1 ELISA (both obtained from R&D Systems, 
Abingdon, UK). 
Statistical analysis – Statistical analyses were performed with SPSS 20 (SPSS 
Inc., Chicago, IL) and OriginPro 8G (Origin Lab, Northampton, MA). Results in Fig. 2 
and Fig. 5 are shown as mean ± standard deviation (SD). All other data are presented as 
boxplot figures with medians and quartiles. Whiskers represent 5% and 95% confidence 
intervals, * represent 1% and 99% confidence intervals. Linear regression was used to 
assess the influence on inflammatory mediator expression / tissue damage markers 
(dependent variables). The different treatment modalities (LPS, LPS+HFIP, 
LPS+sevoflurane, and HFIP) were included in the linear regression model as binary, 
independent predictors. If applicable, different measurement time points were addressed 
using a categorical, independent predictor variable. Control animals (or control cells, 
respectively) were used as reference category. All results are illustrated as B 
coefficients and corresponding 95% confidence intervals (Tables 1-8). Using binary 
independent predictor variables, the resulting B coefficients represent the averaged 
effect difference during the experiment in relation to untreated control animals or 
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control cells (reference category). For gene array and pathway analyses, we considered 
p < 0.01 as significant. For all other analyses a p-value < 0.05 was considered 
significant.  
 
RESULTS 
HFIP attenuates endotoxin-induced systemic inflammation – Systemic 
inflammation was evaluated hourly by assessment of a subset of surrogate markers in 
plasma which have proven to be prognostic factors for severity and outcome of sepsis, 
such as MCP-1, IL-6, and CINC-1 [21-23]. Stimulation with LPS provoked a rise in the 
plasma concentration of MCP-1, IL-6, and CINC-1 confirming the presence of a 
systemic inflammatory response in our model (Fig. 2A-C). Peak values were found 6 
hours after administration of LPS: 5027 ng/mL for MCP-1, 101 ng/mL for IL-6, and 
867 ng/mL for CINC-1. The LPS-induced secretion of MCP-1 and IL-6 protein 
decreased 43% and 72%, respectively, when animals were treated with HFIP (both 
p<0.001). Interleukin-6 concentration in HFIP-treated animals was comparable to 
control animals at the end of the experiment. In animals treated with HFIP slightly 
higher levels of CINC-1 were observed in plasma (mean difference +63ng/mL). 
Sevoflurane, the precursor of HFIP, reduced MCP-1 secretion by 47% (p<0.001) 
whereas IL-6 secretion was not affected by sevoflurane. Cytokine-induced neutrophil 
chemoattractant-1 was reduced by 76% (p<0.001) in endotoxemic animals treated with 
sevoflurane. Detailed changes in plasma concentrations of inflammatory mediators are 
listed in Table 1. Taken together, the data indicate that LPS-induced secretion of plasma 
inflammatory mediators is attenuated by HFIP and sevoflurane.  
HFIP reduces the production inflammatory mediator mRNA in tissue – To 
examine whether HIFP and sevoflurane have a similar effect on production of 
inflammatory mediators in tissue as observed in the plasma, we determined mRNA 
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levels of MCP-1, IL-6, and CINC-1 in kidney, liver, lung and spleen (Tables 2-5). 
While these different tissues were assessed, a special focus was placed on the kidney 
and the liver as these organs are of particular interest in models of endotoxemia [15, 
24]. In all organs, elevated mRNA levels of MCP-1, IL-6, and CINC-1 were observed 
upon stimulation with LPS, which is in accordance with the results from plasma 
measurements. While messenger RNA of all three inflammatory mediators was 
attenuated in all organs by HIFP treatment (all p<0.01), this effect could not be 
demonstrated for sevoflurane. In kidneys, sevoflurane decreased the expression of 
proinflammatory mediator mRNA, except for CINC-1, which remained unaffected 
(Table 2). In liver and spleen tissue, sevoflurane attenuated the LPS-stimulated 
elevation of all three inflammatory mediator mRNAs (Table 3 and 5). In the lung, 
sevoflurane reduced the amount of MCP-1 mRNA by 29% (p<0.001), but there was not 
a notable difference in IL-6 and CINC-1 mRNA levels (Table 3). Details of the changes 
in inflammatory mediator expression profiles are described in Tables 2-5. In summary, 
HFIP and to a lesser extent sevoflurane reduced LPS-induced mRNA production of 
proinflammatory mediators in kidneys, liver, lung, and spleen. 
Decreased effector cell recruitment in kidney and liver in HFIP-treated animals 
– Dysfunction of the kidneys and the liver greatly contribute to the severity and 
outcome of systemic inflammation [25, 26]. Effector cells migrate towards the site of 
tissue injury along gradients of proinflammatory mediators. Excessive amounts of 
cytokines and an overshooting recruitment of activated effector cells might convert the 
normally beneficial effects of inflammation into a condition that is damaging to the host 
[27]. In order to examine the biological relevance of increased expression of 
inflammatory mediator mRNA in tissues, we quantified the amount of neutrophils in 
kidney and liver by immunofluorescence staining. In accordance with the observed 
elevation in inflammatory mediator mRNA, an increased number of neutrophils was 
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observed in the parenchyma after LPS stimulation (Tables 2 and 3). Administration of 
HFIP or sevoflurane reduced the LPS-induced neutrophil influx in both organs to levels 
comparable to that observed in control animals (p<0.01). These data illustrate that the 
decreased amount of inflammatory mediator mRNA, resulting from treatment with 
HFIP or sevoflurane, also translates into reduced effector cell recruitment. 
HFIP-mediated attenuation of tissue damage and resulting effect on organ 
function – To estimate possible protective effects of the application of HFIP, we 
evaluated different tissue damage markers of the kidneys (Table 2), the liver (Table 3), 
the lung (Table 4) as well as the spleen (Table 5), focusing on apoptosis and necrosis. 
Whenever possible, we also tried to put the amount of tissue injury into context with the 
respective parameters of organ function. With regard to apoptosis, no difference in 
caspase-3 activity was observed in the kidneys in the different groups (overall p-value: 
0.081) (Table 2). As a marker of tubular damage, α1-microglobulin was measured in 
urine. Increased α1-microglobulin after LPS stimulation was attenuated by both HFIP (-
23%) and sevoflurane (-60%) suggesting a prevention of sepsis-induced tubular damage 
[28] (p-values<0.001). In septic animals, plasma creatinine and BUN concentrations 
were increased (by 24 mmol/L and by 3 mmol/L), which is consistent with there being 
impaired renal function. Administration of HFIP lowered the plasma creatinine 
concentration by 4 mmol/L (p<0.05), while BUN levels were not affected. In contrary 
to HFIP, sevoflurane aggravated the rise in creatinine (+17 mmol/L) and BUN 
concentration (+5 mmol/L) in comparison to animals treated with LPS alone (p<0.001). 
In liver tissue, LPS stimulation increased caspase-3 activity, and this effect was reduced 
by 48% and by 57% when animals received HFIP or sevoflurane, respectively (p<0.01, 
Table 3). Aspartate transaminase, a typical hepatocyte necrosis marker, was not 
influenced by LPS or by HFIP, but elevated levels were observed in animals receiving 
sevoflurane, independent of sepsis. In all animals, bilirubin concentrations were below 
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detection levels (<1.7 µmol/L).  In the lung, caspase-3 activity was not affected by LPS 
stimulation, HFIP, or sevoflurane administration (overall p-value: 0.2, Table 4). Arterial 
oxygen partial pressures in animals remained unchanged with exception of the 
sevoflurane group, in which lower oxygen partial pressures were observed. Arterial 
oxygen saturation was >96% in all animals during the entire experiment. In the spleen, 
LPS induced a 2.4-fold increase in caspase-3 activity which was only slightly mitigated 
by HFIP but reached levels similar to that of control animals upon treatment with 
sevoflurane (Table 5). Taken together, HFIP and sevoflurane attenuated LPS-induced 
tissue injury. With regard to the kidneys, HFIP also attenuated LPS-induced impairment 
of renal function. 
Stabilization of the blood pressure drop after HFIP administration in 
endotoxemic animals – In animals receiving LPS, mean arterial blood pressure (MAP) 
decreased from 146 mmHg to 60 mmHg over the duration of the experiment. The 
administration of HFIP stabilized the LPS-induced initial drop in MAP (Fig. 3): the 
blood pressure recovered after 2 hours, reaching a value of 102 mmHg at the end of the 
experiment (p<0.001, R2: 0.458). This was not observed in sevoflurane treated animals 
where the mean arterial pressure dropped from 126 mmHg to 59 mmHg over the time of 
the experiment. During the 30 minutes of sevoflurane administration, a particularly 
pronounced decrease in MAP was observed which might be the result of an overlapping 
anesthetic and cardiovascular effect of sevoflurane and propofol.  These results indicate 
that administration of HFIP prevents the LPS-induced drop in blood pressure. 
Effects of HFIP on acid/base and electrolyte status – Independent of the injury 
and the treatment, only marginal differences in pH, pCO2 and bicarbonate values were 
found (Table 6). In animals receiving sevoflurane, a small change in lactate level was 
measured (mean difference relative to control over 6 hours: +0.6 mmol/L, p<0.001). All 
LPS-treated animals had reduced bicarbonate levels, which was not reflected by a 
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decrease in the pH value. Only minimal changes in plasma electrolytes were measured, 
but worthy of note was the drop in chloride levels in the sevoflurane group by 12 
mmol/L (p<0.001) (Table 6). 
Gene expression analysis in human microvascular endothelial cells after 
exposure to HFIP – To gain insight into the underlying mechanism(s) of the 
immunomodulatory effect of HFIP, we performed a gene expression profile analysis of 
human microvascular endothelial cell (HMVEC)  exposed to LPS [19]. A total of 42545 
probes were expressed on the microarray. A heat map representation of the gene 
expression profiles in response to HFIP exposure is illustrated in Fig. 4A. LPS 
stimulation of HMVEC significantly affected 1925 gene transcripts of which 1022 were 
downregulated (284 with ≥2-fold change), and 903 upregulated (378 with ≥2-fold 
change). With the application of HFIP alone, 2746 transcripts significantly changed. Of 
these genes, 1406 genes were downregulated (444 with ≥2-fold change) and 1340 were 
upregulated (344 with ≥2-fold change). To illustrate the influence of HFIP on LPS-
stimulated changes in gene expression, different Venn diagrams with intersections of 
transcripts showing a ≥2-fold change by both LPS and HFIP are shown in Fig. 4B and 
C. One hundred thirty nine of the 903 transcripts upregulated by LPS stimulation were 
downregulated by HFIP (48 of 378 transcripts with ≥2-fold change, Fig. 4B). Two 
hundred thirteen of 1022 transcripts downregulated by LPS stimulation were 
upregulated by HFIP treatment (59 of 284 transcripts with ≥2-fold change, Fig. 4C). 
Fifty-four transcripts that were already upregulated by LPS stimulation were further 
increased by HFIP (17 with ≥2-fold change), while 18 transcripts already 
downregulated by LPS stimulation were further decreased by the application of HFIP (1 
with ≥2-fold change). We suspected important changes in gene expression induced by 
HFIP within the TLR4 pathway – the mammalian LPS sensor. To specifically address 
the postulated impact of HFIP on this particular pathway, an enrichment analysis using 
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the GeneGO MetaCore framework was performed. Downstream of TLR4 (Fig. S1), we 
found a significant downregulation in response to HFIP treatment in NF-κΒ and AP-1 
dependent inflammatory-mediator expression in LPS-stimulated HMVEC (Fig. 4D). 
Based on these results, we assessed the influence of HFIP on both NF-κΒ and AP-1 in 
LPS-stimulated HMVEC using gene-reporter luciferase assays (Fig. 4E and 4F). 
Hexafluoro-2-propanol significantly reduced mean LPS-induced NF-κΒ activity by 
73% (p=0.005, R2: 0.424), wherease there was no effect of HFIP on AP-1 activity 
(overall p=0.323). Taken together, HFIP-induced immunomodulation in LPS-stimulated 
HMVEC is associated with reduced activity of NF-κΒ. 
Localization of HFIP-immunomodulation within the toll-like receptor 4 (TLR4) 
signaling pathway – To further explore the mechanism and the site of action of HFIP on 
LPS-induced secretion of inflammatory mediators, the TLR4 pathway upstream of NF-
κΒ was assessed. Endotoxin-induced inflammatory cytokine release is mediated by the 
TLR4 signaling pathway involving activation of interleukin-1 receptor-associated 
kinase 1/2 (IRAK 1/2), tumor necrosis factor (TNF) receptor-associated factor 6 
(TRAF6), NF-kappa-beta-inducing kinase (NIK, MAP3K14), I kappa B kinases (IKK) 
which ultimately increase NF-κΒ activity (Fig. 5). In accordance with results from gene 
expression analysis, secretion of IL-6 and CINC-1 protein by LPS-stimulated HMVEC 
was attenuated when cells were treated with HFIP (Fig. 6A-B). To examine whether 
HFIP modulates the TLR4 pathway prior to NIK activation, we stimulated the cells with 
TNF-α instead of LPS. In this cascade, cytokine release is mediated through TRAF2, 
NIK and IKK, sharing NIK, IKK and NF-κΒ as common downstream elements (Fig. 5). 
Similar to that observed with LPS, HFIP reduced the expression of inflammatory 
mediators induced by TNF-α exposure (Fig. 6C-D, Table 7). The persistence of the 
HFIP effect suggests that HFIP may modulate signaling downstream of TRAF6 and 
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TRAF2. We thus next stimulated cells with PMA, which directly provokes cytokine 
secretion through stimulation of protein kinase C (PKC) [29, 30] and subsequent 
activation of IKK (Fig. 5). In response to PMA stimulation, HFIP reduced IL-6 and 
CINC-1 protein secretion (Fig. 6E-F, Table 8) suggesting that the modulation of 
inflammatory mediator secretion is located downstream of IKK. 
 
DISCUSSION 
We demonstrate HFIP-mediated attenuation of endotoxin-induced inflammatory 
processes in rats as reflected by decreases in surrogate markers of sepsis in plasma, 
decreased effector cell invasion into vital organs, and reduced tissue damage. In 
addition, administration of HFIP improved hemodynamic stability of the animals. 
Pathway analysis in an in vitro model of endotoxin-induced endothelial cell injury 
revealed that the attenuation of inflammatory mediator secretion is mediated by the 
attenuation of NF-κΒ activation and dependent transcript expression.  
In recent work, we showed using the cecal ligation and puncture (CLP) model of 
sepsis that rats had a remarkable 7-day survival benefit when treated with HFIP [14]. 
While the study addressed important outcome parameters, the underlying mechanisms 
of HFIP that increased survival remained unclear. The present study therefore focused 
on the orchestration of the inflammatory response in an early phase of sepsis and 
demonstrated that HFIP decreased inflammatory mediator secretion and tissue damage 
in early endotoxemia. Differences in the effect of HFIP and sevoflurane might be 
explained by the different routes of administration, by different pharmacokinetics (long 
elimination half-life of HFIP versus fast wash-out of sevoflurane) [20], or by 
differences in the molecular structure (hydrophilicity, hydrophobicity). In LPS-
stimulated animals receiving sevoflurane treatment, an initial drop in blood pressure 
was observed which is most likely due to the overlap of the two anaesthetics propofol 
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and sevoflurane (stopping the propofol infusion and starting the application of the 
volatile anaesthetic) in already impaired animals. The phase of low blood pressure with 
impaired organ perfusion would explain increased tissue damage markers such as BUN, 
creatinine, and AST as well as the lower arterial partial pressure of oxygen in the 
LPS+sevoflurane group. Despite this initial drop in blood pressure, the known anti-
inflammatory effects of sevoflurane were confirmed in the present model of early phase 
endotoxemia [10, 31]. 
The more advanced states of sepsis are in particular characterized by a loss of 
key immune effector cells which die due to sepsis-mediated apoptosis [32] and 
ultimately lead to a failure of host defense mechanisms [33]. The prevention of sepsis-
induced apoptosis therefore represents an interesting therapeutic target and has been 
shown to successfully ameliorate survival [33-35]. In the present article, we observed 
that HFIP and sevoflurane do not only modulate inflammatory mediator secretion, but 
also reduce apoptosis in liver and spleen of endotoxemic animals. Thus, HFIP and 
sevoflurane clearly differ from other therapeutic approaches aiming solely at the 
attenuation of the ‘cytokine storm’ in sepsis.  
Gene expression and pathway analysis illustrated that HFIP-induced 
downregulation of inflammatory mediators was likely due to inhibition of NF-κB 
activation which is well known to play a crucial role in orchestrating the inflammatory 
response. Based on the results from the microarray analysis and gene-reporter luciferase 
assays, we assume that a major part of the anti-inflammatory effects of HFIP is 
mediated at the level of or downstream of the IKK complex. With reference to the 
results of our experiments with TNF-α and PMA must certainly be considered that 
amongst all these pathways flow equilibria might exist. There is, however, already 
limited data in support of NF-κB-dependent suppression of inflammatory mediators by 
volatile anesthetics [36, 37], which is in line with the present results.  
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While our findings suggest HFIP-induced protection may be clinically very 
important, these promising results should be tempered as successful translation may be 
limited due to important clinical features of human sepsis which are not adequately 
modelled by experiments in rodents. Furthermore, a single LPS injection is unlikely to 
mimic the inflammatory responses in human sepsis [15, 38], as highlighted in previous 
studies where  therapeutic strategies that have been promising in endotoxin-based 
rodent models where unsuccessful in clinical practice [39, 40]. Potentially important 
factors determining survival such as genetic heterogeneity and gender variability of the 
inflammatory response, different time points of sepsis onset, as well as the presence of 
pre-existing comorbidities should also be addressed [15, 38, 41]. No model will ever 
fully reflect the complexity of human sepsis, but studies in intact organisms allow the 
observation of complex interactions between organ systems and analysis of underlying 
mechanisms. With regard to in vivo sepsis models, the best preclinical investigation 
consists of observations in a combination of different animal models comprising 
different species and different types of sepsis induction [38]. The strong anti-
inflammatory effects of HFIP in our Wistar rat endotoxaemia model – complementary 
to our observation of improved survival in a CLP mouse model of sepsis [14] – 
strengthens the proposition of HFIP as a future treatment modality in sepsis. Being the 
chief metabolite of sevoflurane, a large number of patients have been exposed to low 
doses of HFIP, and  data on the metabolism and pharmacokinetics of HFIP is available 
[20]. Presupposing even more detailed knowledge on the molecular mechanisms of its 
anti-inflammatory effects, the intravenous administration of HFIP may provide a novel 
therapeutic tool in the treatment of systemic inflammation and sepsis. 
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FIGURE LEGENDS 
Figure 1. Illustration of experimental setting: after a single injection of 
lipopolysaccharide (LPS), male Wistar rats were treated either with hexafluoro-2-
propanol (HFIP) or with sevoflurane. An analysis of inflammatory mediators and tissue 
damage markers was performed (kidney, lung, liver, and spleen tissue) six hours after 
LPS injection (A). In human lung microvascular endothelial cells, gene expression and 
pathway analysis was performed after LPS and HFIP exposure (B). MCP-1=Monocyte 
chemoattractant protein-1, IL-6=interleukin-6, CINC-1=cytokine-induced neutrophil 
chemoattractant protein-1, BALF=bronchoalveolar lavage fluid, AST=aspartate 
transaminase, BUN=blood urea nitrogen. 
 
Figure 2. HFIP and sevoflurane treatment attenuates plasma inflammatory mediator 
secretion in LPS-stimulated rats. Monocyte chemoattractant protein-1 (MCP-1), 
interleukin-6 (IL-6) and cytokine-induced neutrophil chemoattractant-1 (CINC-1) 
protein concentrations were determined hourly (0-6 hours, T0-T6) in plasma of 
lipopolysaccharide (LPS)-treated rats simultaneously exposed to either hexafluoro-2-
propanol (HFIP) or sevoflurane (A, B, C). Values represent mean±SD. 
 
Figure 3. HFIP induces a stabilization of mean arterial pressure (MAP) in endotoxemic 
animals. Using invasive blood pressure monitoring, we assessed mean arterial blood 
pressure every 10 minutes after injection of lipopolysaccharides (LPS) in male Wistar 
rats. Hexafluoro-2-propanol (HFIP) or sevoflurane was administered over 30 minutes 
(indicated by the blue bar). MAP of control and HFIP-treated animals is shown in 
supplementary Fig. S1.T0-T6=time point 0 to 6 hours. Values are mean±SD. 
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Figure 4.  Hexafluoro-2-propanol (HFIP) reduces lipopolysaccharide-induced NF-
kappa B activity in endothelial cells (HMVEC). Heat map illustrating the effect of 
lipopolysaccharide (LPS) stimulation on HMVEC mRNA expression in absence or 
presence of hexafluoro-2-propanol (HFIP) (A). Venn diagrams representing the number 
of transcripts regulated upon LPS-stimulation and those affected by HFIP (threshold=1, 
p<0.01) (B, C). Summary of significantly different transcripts within the toll-like 
receptor 4 (TLR4)-downstream network (gene symbol and probe name) in LPS-
stimulated cells which underwent a treatment with HFIP (D). Gene activity of NF-kappa 
B and activator protein 1 (AP-1) in HMVEC measured by firefly luciferase assay (E, F). 
Whiskers represent 5% and 95% confidence intervals, * represent 1% and 99% 
confidence intervals. LPS=lipopolysaccharide, HFIP=hexafluoro-2-propanol, 
PBS=phosphate-buffered saline. 
 
Figure 5.  Schematic illustration of the TLR4-downstream / NF-κB upstream network. 
Lipopolysaccharide (LPS)-induced inflammatory cytokine release is mediated by the 
toll like-receptor 4 (TLR4) pathway involving activation of interleukin-1 receptor-
associated kinase 1/2 (IRAK 1/2), tumor necrosis factor receptor-associated factor 6 
(TRAF6), nuclear factor-κ B(NF-κB)-inducing kinase (NIK, MAP3K14), I kappa B 
kinases (IKK), and subsequent upregulation of NF-κB. Tumor necrosis factor-α (TNF-
α)-related cytokine release is mediated through TNF receptor-associated factor 2 
(TRAF2), NIK/MAP3K14, and IKK activating NF-κB. Phorbol-12-myristate-13-acetate 
(PMA) directly provokes cytokine secretion by activation of protein kinase C (PKC) 
through IKK and subsequent NF-κB activation. 
 
Figure 6.  Attenuation of inflammatory mediators by hexafluoro-2-propanol (HFIP) is 
mediated at the level of IKK or its downstream effectors. LPS-induced (A, B) and 
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TLR4-mediated (C, D) stimulation of Interleukin-6 protein (IL-6) and cytokine-induced 
neutrophil chemoattractant protein-1 (CINC-1) secretion in human microvascular 
endothelial cells (HMVEC). Exposure of HMVEC to PMA (E, F). MyD88=myeloid 
differentiation primary response 88; TRADD=tumor necrosis factor receptor-1-
associated protein.  
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TABLES 
 
Table 1. Linear regressions on plasma inflammatory mediators and hemodynamics 
 LPS LPS+HFIP LPS+Sevoflurane HFIP Time R2 
Cytokines 
MCP-1, ng/mL 3329 (2679, 3979) a 1896 (1142, 2650) a 1748 (1070, 2427) a -77 (-826, 672) a 404 (301, 506) a 0.498 
IL-6, ng/mL 50 (35, 65) a 14  (-3, 32) 68 (52, 84) a 1 (-17, 19) 11 (9, 14) a 0.476 
CINC-1, ng/mL 497 (321, 673) a 560 (356, 765) a 120 (-63, 303)  79 (-127, 286) 99 (71, 127) a 0.333 
Hemodynamics 
MAP, mmHg -19 (-23, -15) a 1 (-4, 5) -26 (-31, -22) a 0 (-4, 5) -2 (-2, -1) a 0.458 
The table contains the B coefficients (95% confidence intervals) of the linear regressions. The different treatments (LPS, LPS+HFIP, 
LPS+Sevoflurane, HFIP) were addressed using binary predictors, while the measurement time point was entered as categorical independent 
predictor. The resulting B coefficient represents the mean effect difference in relation to untreated control animals (reference category). MCP-1: 
monocyte chemoattractant protein-1, IL-6: interleukin-6 protein, CINC-1: cytokine-induced neutrophil chemoattractant-1 protein, MAP: mean 
arterial pressure, LPS: lipopolysaccharide, HFIP: hexafluoro-2-propanol. Significance: a p<=0.001, b p<0.01, c p<0.05.  
Hexafluoro-2-propanol in endotoxemic rats 
 
 
Table 2. Linear regressions on inflammatory mediator, organ damage marker as well as organ function of the kidney 
Marker LPS LPS+HFIP LPS+Sevoflurane HFIP R2 
MCP-1 mRNA, n-fold 527 (396, 658) a 257 (106, 408) b 280 (144, 416) a 0 (-151,151) 0.785 
IL-6 mRNA, n-fold 580 (410, 749) a 366 (170, 562) a 390 (213, 566) a 0 (-196, 195) 0.732 
CINC-1 mRNA, n-fold 71 (52, 90) a 36 (15, 58) b 71 (52, 91) a 0 (-22, 22) 0.807 
Neutrophils, cm-2 842 (453, 1231) a 6 (-414, 426) -46 (-496, 403) 11 (-361, 384) 0.710 
Caspase-3 activity, a.u. overall p-value = 0.081 
α-microglobulin, µg/mL 168 (103, 234) a 127 (57, 196) a 58 (-6, 122) 45 (-6, 122) 0.663 
BUN, mmol/L 3 (1, 5) a 4 (2, 6) a 8 (6, 10) a 0 (-3, 2) 0.789 
Plasma creatinine, mmol/L 24 (4, 44) c 20 (-3, 44) 41 (20, 62) a -9 (-32, 14) 0.524 
The table contains the B coefficients (95% confidence intervals) of the linear regression. The different treatments (LPS, LPS+HFIP, 
LPS+Sevoflurane, HFIP) were addressed using binary predictors, while the measurement time point was entered as categorical independent 
predictor. Using binary independent predictor variables, the resulting B coefficients represent the mean effect difference in relation to untreated 
control animals (reference category). MCP-1: monocyte chemoattractant protein-1, IL-6: interleukin-6 protein, CINC-1: cytokine-induced 
neutrophil chemoattractant-1 protein, BUN: blood urea nitrogen. LPS: lipopolysaccharide, HFIP: hexafluoro-2-propanol. Significance: a 
p<=0.001, b p<0.01, c p<0.05. 
Hexafluoro-2-propanol in endotoxemic rats 
 
 
Table 3. Linear regressions on inflammatory mediator and organ damage marker of the liver 
Marker LPS LPS+HFIP LPS+Sevoflurane HFIP R2 
MCP-1 mRNA, n-fold 19 (13, 26) a 13 (5, 20) a 10 (3, 16) b 0 (-7, 7) 0.680 
IL-6 mRNA, n-fold 277 (213, 342) a 254 (180, 329) a 180 (112, 247) a 0 (-75, 74) 0.826 
CINC-1 mRNA, n-fold 50 (38, 63) a 46 (32, 61) a 11 (-2, 24) 0 (-15, 14) 0.840 
Neutrophils, cm-2. 867 (323, 1411) b 512 (-102, 1127) 37 (-619, 694) 417 (-138, 972) 0.458 
Caspase-3 activity, a.u. 4.4 (3.1, 5.7) a 2.3 (0.9, 3.8) b 1.9 (0.7, 3.2) b  0.2 (-1.3, 1.6) 0.727 
AST, U/L 116 (-42, 275) 17 (-165, 200) 224 (59, 389) b 62 (-121, 244) 0.280 
The table contains the B coefficients (95% confidence intervals) of the linear regression. The different treatments (LPS, LPS+HFIP, 
LPS+Sevoflurane, HFIP) were addressed using binary predictors, while the measurement time point was entered as categorical independent 
predictor. Using binary independent predictor variables, the resulting B coefficients represent the mean effect difference in relation to untreated 
control animals (reference category). MCP-1: monocyte chemoattractant protein-1, IL-6: interleukin-6 protein, CINC-1: cytokine-induced 
neutrophil chemoattractant-1 protein. AST: Aspartate transaminase. LPS: lipopolysaccharide, HFIP: hexafluoro-2-propanol. Significance: a 
p<=0.001, b p<0.01, c p<0.05. 
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Table 4. Linear regressions on inflammatory mediator, organ damage marker as well as organ function of the lung 
Marker LPS LPS+HFIP LPS+Sevoflurane HFIP R2 
MCP-1 mRNA, n-fold 116 (86, 146) a 82 (49, 114) a 82 (51, 114) a 0 (-35, 35) 0.765 
IL-6 mRNA, n-fold 76 (48, 103) a 59 (29, 88) a 78 (49, 107) a 0 (-31, 32) 0.677 
CINC-1 mRNA, n-fold 3 (2, 5) a 2 (1, 4) b 3 (1, 4) a 0 (-2, 2) 0.565 
BALF MCP-1 protein, ng/mL 82.8 (56.4, 109.2) a 35.4 (7.2, 63.7) c 19.5 (-8.0, 47.0) 0.7 (-29.8, 31.2) 0.687 
BALF IL-6 protein, ng/mL 6.3 (4.3, 8.3) a 5.9 (3.8, 8.1) a 2.6 (0.5, 4.7) c 0.3 (-2.0, 2.7) 0.706 
BALF CINC-1 protein, ng/mL 5.3 (1.6, 9.0) b 4.0 (-0.1, 8.0) 1.9 (1.9, 5.7) -0.1 (-4.4, 4.1) 0.338 
Caspase-3 activity, a.u. overall p-value = 0.2 
pO2, kPa d -2.3 (-4.7, 0.0) -1.7 (-4.4, 0.9) -10.6 (-13.4, -7.8) a -1.0 (-3.7, 1.7) 0.405 
The table contains the B coefficients (95% confidence intervals) of the linear regression. The different treatments (LPS, LPS+HFIP, 
LPS+Sevoflurane, HFIP) were addressed using binary predictors, while the measurement time point was entered as categorical independent 
predictor. Using binary independent predictor variables, the resulting B coefficients represent the mean effect difference in relation to untreated 
control animals (reference category). MCP-1: monocyte chemoattractant protein-1, IL-6: interleukin-6 protein-1, CINC-1: cytokine-induced 
neutrophil chemoattractant-1 protein. LPS: lipopolysaccharide, HFIP: hexafluoro-2-propanol, BALF: bronchoalveolar lavage fluid. Significance: a 
p<=0.001, b p<0.01, c p<0.05. d Regarding the pO2 levels, we also introduced the measurement time point as a predictor in the regression analysis: 
the b coefficient was -0.8 with a confidence interval of -1.5 to -0.1 (p<0.05). 
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Table 5. Linear regressions on inflammatory mediator and organ damage marker of the spleen 
Marker LPS LPS+HFIP LPS+Sevoflurane HFIP R2 
MCP-1 mRNA, n-fold 49 (37, 62) a 41 (28, 54) a 43 (30, 56) a 0 (-14, 14) 0.803 
IL-6 mRNA, n-fold 139 (105, 174) a 94 (57, 131) a 101 (65, 137) a 0 (-40, 40) 0.784 
CINC-1 mRNA, n-fold 146 (100, 192) a 128 (79, 177) a 74 (26, 121) b 0 (-53, 52) 0.711 
Caspase-3 activity, a.u. 2.4 (1.5, 3.2) a 2.1 (1.1, 3.1) a -0.5 (-1.4, 0.4) -0.6 () 0.778 
The table contains the B coefficients (95% confidence intervals) of the linear regression. The different treatments (LPS, LPS+HFIP, 
LPS+Sevoflurane, HFIP) were addressed using binary predictors, while the measurement time point was entered as categorical independent 
predictor. Using binary independent predictor variables, the resulting B coefficients represent the mean effect difference in relation to untreated 
control animals (reference category). MCP-1: monocyte chemoattractant protein-1, IL-6: interleukin-6 protein, CINC-1: cytokine-induced 
neutrophil chemoattractant-1 protein. LPS: lipopolysaccharide, HFIP: hexafluoro-2-propanol. Significance: a p<=0.001, b p<0.01, c p<0.05. 
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Table 6. Linear regressions on acid/base status and plasma electrolytes 
 LPS LPS+HFIP LPS+Sevoflurane HFIP Time R2 
Acid/Base status 
pH 0.08 (0.06, 0.12) a 0.09 (0.06, 0.12) a 0.09 (0.06, 0.11) a 0.00 (-0.03, 0.03) -0.01 (-0.02, -0.01) a 0.472 
pCO2, kPa 0.8 (0.4, 1.2) a 1.0 (0.5, 1.4) a 1.1 (0.6, 1.6) a 0.4 (-0.1, 0.8) -0.4 (-0.5, -0.3) a 0.416 
HCO3-, mmol/L -2.1 (-3.1, -1.1) a -2.1 (-3.2, -1.0) a -2.2 (-3.2, -1.2) a 0.6 (-0.4, 1.7) -0.8 (-1.1, -0.6) a 0.426 
Lactate, mmol/L 0.3 (0.0, 0.7) 0.0 (-0.4, 0.4) 0.6 (0.3, 1.0) a -0.2 (-0.6, 0.2) 0.1 (0.0, 0.2) 0.181 
Plasma electrolytes 
Potassium, mmol/L 0.1 (-0.2, 0.3) 0.3 (0.0, 0.5) c 0.2 (-0.1, 0.4) -0.1 (-0.4, 0.2) 0.2 (0.1, 0.2) a 0.253 
Sodium, mmol/L 0 (-1, 1) 2 (1, 3) b -2 (-3, -1) b 0 (-1, 1) 0 (0, 1) c 0.306 
Chloride, mmol/L 2 (0, 3) b 3 (1, 4) a -12 (-14, -10) a 0 (-2, 1) 1 (1, 2) a 0.758 
The table contains the B coefficients (95% confidence intervals) of the linear regression. The different treatments (LPS, LPS+HFIP, 
LPS+Sevoflurane, HFIP) were addressed using binary predictors, while the measurement time point was entered as categorical independent 
predictor. Using binary independent predictor variables, the resulting B coefficients represent the mean effect difference in relation to untreated 
control animals (reference category). LPS: lipopolysaccharide, HFIP: hexafluoro-2-propanol. Significance: a p<=0.001, b p<0.01, c p<0.05. 
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Table 7. Linear regression on inflammatory response in HMVEC after stimulation with tumor necrosis factor-α (TNF-α) 
Marker TNF-α TNF-α +HFIP HFIP R2 
IL-6, pg/mL 75 (58, 91) a 36 (19, 53) b -1 (-18, 16) 0.982 
CINC-1, pg/mL 3956 (2389, 5523) a 3160 (1592, 4727) a 128 (-1439, 1695) 0.801 
The table contains the B coefficients (95% confidence intervals) of the linear regression. The different treatments (TNF-α, TNF-α+HFIP, HFIP) 
were addressed using binary predictors. Using binary independent predictor variables, the resulting B coefficients represent the mean effect 
difference in relation to untreated control cells (reference category).  CINC-1: cytokine-induced neutrophil chemoattractant-1 protein. IL-6: 
interleukin-6 protein. TNF-α: tumor necrosis factor α, HFIP: hexafluoro-2-propanol. Significance: a p<=0.001, b p<0.01. 
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Table 8. Linear regression on inflammatory response in HMVEC after stimulation with phorbol 12-myristate 13-acetate (PMA) 
Marker PMA PMA+HFIP HFIP R2 
IL-6, pg/mL 926 (715, 1138) a 813, (602, 1025) a -8 (-267, 252) 0.762 
CINC-1, pg/mL 1723 (1497, 1950) a 1341 (1115, 1567) a -117 (-394, 160) 0.906 
The table contains the B coefficients (95% confidence intervals) of the linear regression. The different treatments (PMA, PMA+HFIP, HFIP) were 
addressed using binary predictors. Using binary independent predictor variables, the resulting B coefficients represent the mean effect difference in 
relation to untreated control cells (reference category).  CINC-1: cytokine-induced neutrophil chemoattractant-1 protein. IL-6: interleukin-6 protein. 
PMA: phorbol 12-myristate-13-acetate, HFIP: hexafluoro-2-propanol. Significance: a p<=0.001. 
  
Hexafluoro-2-propanol in endotoxemic rats 
 
 
Figure 1 
 
  
Hexafluoro-2-propanol in endotoxemic rats 
 
 
Figure 2 
 
 
 
Figure 3 
Hexafluoro-2-propanol in endotoxemic rats 
 
 
 
  
Hexafluoro-2-propanol in endotoxemic rats 
 
 
Figure 4 
 
  
Hexafluoro-2-propanol in endotoxemic rats 
 
 
Figure 5 
 
  
Hexafluoro-2-propanol in endotoxemic rats 
 
 
Figure 6 
 
